



M Marre

Kontakt

M Marre

Publikationen (2)

Mu B, Sterner M, Tang M, Tarnow L, Tuomi T, van't Riet E, van Leeuwen N, Varga T, Vestmar M, Walker M, Wang B, Wang Y, Slagboom P, Nielsen A, Nijpels G, Nilsson P, Palmer C, Rayner N, Renström F, Ribel-Madsen R, Robertson N, Rolandsson O, Rossing P, Schwartz T, Wu H, Xi F, Yengo L, Laakso M, Groop L, Christensen C, Brandslund I, Lauritzen T, Witte D, Linneberg A, Jørgensen T, Hansen T, Wang J, Nielsen R, McCarthy M, Froguel P, Yu C, Zhang X, Zhang J, Zhang Q, Zhang W, Zheng H, Zhou Y, Altshuler D, 't Hart L, Franks P, Balkau B, Pedersen O, Morris A, Albrechtsen A, Ladenvall C, Cauchi S, Stančáková A, Andersen G, Astrup A, Banasik K, Bennett A, Bolund L, Charpentier G, Chen Y, Dekker J, Morris A, Skotte L, Grarup N, Li Y, Sparsø T, Tian G, Cao H, Jiang T, Kim S, Korneliusson T, Li Q, Nie C, Wu R, Doney A, Dorkhan M, Forsen T, Kuusisto J, Lajer M, Lantieri O, Li W, Liang H, Liao Q, Liu X, Ma T, Ma X, Manijak M, Marre M, Kristiansen K, Justesen J, Frayling T, Groves C, Gui Y, Hallmans G, Hattersley A, He K, Hitman G, Holmkvist J, Huang S, Jiang H, Jin X, Mokrosiński J. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. *Diabetologia* 2012; 56:298–310.

Marre M, Colagiuri S, Le Thi T, Zdravkovic M, Strand J, Kamaruddin N, Bebakar W, Brändle M, Shaw J, LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic medicine : a journal of the British Diabetic Association* 2009; 26:268–78.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch